This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Neurocrine Biosciences is wagering on the financial upside of a first-of-its kind treatment for the rare disease Prader-Willi syndrome, agreeing on Monday to acquire the drug’s developer, Soleno Therapeutics, in a deal worth $2.9 billion. Neurocrine is paying $53 per share for Soleno, an offer that represents a roughly 34% premium to the biotech’s previous cl ...